D-Wave Quantum: A 91.90% Cancer Result, a Non-Binding Korean Pact and the November 10 Print That Will Grade Both
Published on 11/03/2026 at 16:41 | Editorial boerse-global.de
D-Wave Quantum has spent the past week stacking up headlines — a research award, a preliminary medical study, a Korean memorandum — none of which answers the question that actually matters for the equity: whether any of this converts into revenue. The next scheduled attempt at an answer arrives on November 10, when the company reports third-quarter 2026 results before the opening bell.
Start with the science, because that is where the numbers are most concrete and the caveats most easily lost. Researchers at Florida Atlantic University tested D-Wave's quantum annealing hardware on lung cancer prediction, running a support-vector-machine model on the system. It hit 91.90% accuracy. According to the university, D-Wave's machines delivered the highest accuracy within the study.
The fine print matters as much as the headline. The university explicitly labeled the findings preliminary. The work also rested on a dataset expanded with additional data and on a particular evaluation method — both of which shape what that 91.90% actually means. The result points to a possible use case for the technology. It does not demonstrate performance in routine clinical practice, and it certainly does not translate into a financial contribution to D-Wave on its own.
A Customer's Prize, and What It Does Not Prove
A second health-sector item landed on October 28, when D-Wave disclosed that its customer Shionogi won the quality-of-life category at Japan's NEDO Quantum Computing Challenge. The recognition went to quantum computing research on drug discovery, and the ÂĄ40 million prize is intended to fund Shionogi's further work.
Should investors sell immediately? Or is it worth buying D-Wave Quantum?
That is a genuine research achievement — and a different kind of evidence from the university study. One reflects peer recognition of a customer's work; the other is a result produced under specific test conditions. Neither constitutes proof of productive operations or of a revenue line attributable to D-Wave. Keeping those categories apart does not diminish the award. It simply stops scientific recognition and commercial execution from blurring into a single success story.
The same discipline applies to the agreement signed with LG CNS. The two companies aim to push quantum optimization adoption in South Korea and international markets, moving applications from proof of feasibility into production use, with joint marketing opportunities on the table. The memorandum is expressly non-binding. Its value to shareholders therefore lies in the direction it describes, not in secured business results. Reading a letter of intent as a completed commercial win skips precisely the stage that counts.
What the Tape Is Actually Saying
The share price has been volatile, and none of it maps cleanly onto the news flow. The stock gained 2.8% in one session and fell 5.7% in another — moves that cannot be explained by the study, the prize or the Korean pact. Broader conditions have been part of the story: media reports cited weaker technology names and reduced appetite for speculative growth plays weighing on quantum stocks generally.
Analyst action adds another layer. B. Riley cut its price target on D-Wave to $27 from $40 while keeping its buy rating. A lower target paired with a positive recommendation fits a cautious reading — optimism about the outlook is not the same as certainty about its economic worth. For investors, the more useful question is not whether a given headline stirs confidence, but what kind of progress it actually documents.
That is why the November 10 report carries more weight than any single announcement of the past week. It offers the next real occasion to judge operating development, and it will be measured against a simple standard: the gap between research recognition, non-binding collaboration and demonstrable business. For a company built on a technological future narrative, that distinction is not a footnote. It is the valuation.
Ad
D-Wave Quantum Stock: New Analysis - 3 November
Fresh D-Wave Quantum information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
